Glomerular and paraprotein nephrology · KIMS Secunderabad
Monoclonal Gammopathy of Renal Significance (MGRS) — When a Small Clone Destroys the Kidneys
Monoclonal gammopathy of renal significance (MGRS) is a recently defined clinical entity — introduced by the International Kidney and Monoclonal Gammopathy Research Group in 2012 — to describe kidney disease caused by a small plasma cell or B-cell clone producing a monoclonal immunoglobulin (paraprotein) that deposits in or damages the kidneys, in a patient who does not meet the diagnostic criteria for multiple myeloma, Waldenström's macroglobulinaemia, or other haematological malignancy. The clone is 'small' by haematological criteria (bone marrow plasma cells below 10%, no end-organ damage of myeloma — no CRAB criteria: no hyperCalcaemia, Renal failure from myeloma, Anaemia, or Bone lesions) but its monoclonal product is 'significant' because it is progressively destroying kidney function.
MGRS overturns the historical clinical approach to monoclonal gammopathy of undetermined significance (MGUS) — the traditional teaching was 'watch and wait' for any monoclonal protein below the myeloma threshold. MGRS establishes that even a small plasma cell clone can cause devastating and progressive kidney disease requiring treatment — and that treating the clone (with haematological chemotherapy) is the only way to stop or reverse the kidney damage.
The kidney manifestations of MGRS
| MGRS pattern | Mechanism · Paraprotein | Biopsy finding | Clinical presentation |
|---|---|---|---|
| AL amyloidosis (most common) | Lambda or kappa light chains misfold into amyloid fibrils · Lambda > kappa | Congo red positive · Apple-green birefringence · 8–12nm amyloid fibrils on EM | Nephrotic syndrome · Restrictive cardiomyopathy · Peripheral neuropathy |
| Light chain deposition disease (LCDD) | Kappa light chains deposit as granular non-fibrillar deposits · Kappa > lambda | Congo red negative · Granular electron-dense deposits on EM in GBM and TBM | Nephrotic syndrome · Nodular glomerulosclerosis (resembles diabetic nephropathy) |
| Heavy chain deposition disease (HCDD) | Heavy chain (gamma, alpha, mu) deposits · Gamma most common | Congo red negative · GBM and TBM deposits on EM | Nephrotic syndrome · Hypertension · Haematuria |
| C3 glomerulopathy from monoclonal protein | Paraprotein acts as acquired complement regulatory inhibitor · IgG or IgM | Dominant C3 on IF · Complement alternative pathway activation | Low C3 · Haematuria · Proteinuria · See KIMS C3G page |
| Fibrillary GN and immunotactoid GN | Organised fibrillar or microtubular deposits · IgG or IgM monoclonal | Organised deposits on EM — 10–24nm fibrils (fibrillary) or larger microtubules (immunotactoid) | Haematuria · Proteinuria · Nephrotic syndrome |
Why MGRS is frequently missed
Common pitfalls in MGRS recognition
Serum protein electrophoresis (SPEP) misses 20% of MGRS patients — particularly those with only light chain secretion (no intact immunoglobulin M-spike detectable on SPEP). Serum free light chain (sFLC) assay and urine protein electrophoresis (UPEP) are required to detect all monoclonal proteins.
The patient's haematologist may have dismissed the monoclonal protein as 'MGUS — benign, watch and wait' — without recognising that the kidney biopsy findings require haematological treatment.
The treating nephrologist may have diagnosed the kidney biopsy pattern (amyloidosis, LCDD, membranoproliferative GN) without adequately investigating for the underlying monoclonal driver.
MGRS requires the haematologist and nephrologist to communicate explicitly — the haematologist's 'MGUS' and the nephrologist's 'unexplained nephropathy' are the same patient's disease, caused by the same clone.
Diagnosis at KIMS — joint haematology-nephrology assessment
SPEP, UPEP, and serum free light chains (sFLC)
Comprehensive paraprotein screening. sFLC identifies clones too small for SPEP detection.
Bone marrow biopsy
Confirms the clone size (plasma cell percentage), demonstrates the specific immunoglobulin produced by the clone, and excludes myeloma.
Kidney biopsy with LM + IF + EM at KIMS
Identifies the specific deposit pattern (amyloid, LCDD, fibrillary GN, etc.) and the immunoglobulin subtype depositing in the kidney. EM is the definitive investigation for deposit type (fibrillar vs granular vs microtubular).
Complement studies
For monoclonal C3 glomerulopathy.
VEGF level
For POEMS syndrome.
Treatment — treat the clone
The definitive treatment of MGRS is directed at the underlying plasma cell or B-cell clone — not the kidney manifestations:
AL amyloidosis
Bortezomib-based or daratumumab-based regimens targeting the plasma cell clone. See KIMS Amyloidosis and Multiple Myeloma Kidney pages.
LCDD and HCDD
Bortezomib-based chemotherapy to suppress light or heavy chain production. Renal function improvement occurs if the clone is adequately suppressed before extensive fibrosis.
C3G from monoclonal protein
Treat the clone (bortezomib or rituximab depending on B-cell vs plasma cell clone) + complement-targeted therapy (eculizumab for refractory cases).
Fibrillary GN
Rituximab (anti-CD20) for B-cell clone-associated fibrillary GN. Response rates 50 to 70%.
Kidney transplant
May be considered after the clone has been adequately treated and paraprotein levels are suppressed. Transplant without clone treatment results in rapid recurrence of the MGRS deposits in the transplanted kidney.
MGRS is the paradigm shift in how we treat kidney disease from monoclonal proteins: a small clone that does not yet meet the criteria for myeloma can still require haematological treatment if it is destroying the kidneys. The decision to treat is based on kidney biopsy evidence of monoclonal protein-driven kidney damage — not on the haematological burden of the clone. At KIMS, every MGRS case is reviewed jointly by the nephrology and haematology teams.
Book a Nephrology Consultation for MGRS at KIMS — Joint Haematology-Nephrology Assessment
Frequently Asked Questions — MGRS
MGUS (monoclonal gammopathy of undetermined significance) is a condition where a small plasma cell clone produces a paraprotein but causes no detectable end-organ damage — no kidney disease, no bone lesions, no anaemia. It is managed by observation, with annual paraprotein measurement and monitoring for progression to myeloma. MGRS is a condition where a small plasma cell clone (similar in size to MGUS — not yet meeting myeloma criteria) produces a paraprotein that is actively depositing in and destroying the kidneys. The key difference is the kidney biopsy finding — MGRS requires treatment of the clone to stop kidney destruction; MGUS (without kidney involvement) does not. Many MGRS patients were previously incorrectly managed as MGUS.
MGRS can be put into deep remission — with suppression of the paraprotein to undetectable levels and stabilisation or improvement of kidney function. Cure (elimination of the clone) is achieved in some patients with aggressive chemotherapy, particularly younger patients with AL amyloidosis treated with high-dose chemotherapy and autologous stem cell transplant. For most MGRS patients, the goal is sustained deep haematological remission — suppression of the paraprotein to very low or undetectable levels — which stops further organ damage and allows some recovery of the existing damage. Once established fibrosis or amyloid has replaced functional tissue, recovery of that function is not possible.
The kidney biopsy is the only investigation that: confirms that kidney damage is occurring (rather than monitoring a stable paraprotein), identifies the specific mechanism of kidney damage (amyloid, LCDD, fibrillary GN — each requiring different treatment), confirms that the depositing protein is the monoclonal immunoglobulin of the identified clone (light chain immunostaining on IF matches the sFLC assay result), and provides prognostic information from the degree of fibrosis (informing urgency of treatment and likelihood of renal recovery). Blood tests alone — paraprotein measurement, sFLC, creatinine — cannot provide the mechanism-specific information needed to choose treatment. EM performed in-house at KIMS is the definitive investigation for deposit type characterisation.
No — not every patient with a paraprotein and kidney disease has MGRS. A paraprotein plus kidney disease may represent: true MGRS (the paraprotein is directly causing the kidney disease), coincidental MGUS in a patient whose kidney disease has an unrelated cause (diabetic nephropathy, hypertensive nephrosclerosis, IgA nephropathy — all can occur independently of a paraprotein), or myeloma with kidney involvement (if the bone marrow plasma cell burden meets myeloma criteria). Kidney biopsy confirms which mechanism of kidney damage is present — and immunostaining on the biopsy confirms whether the depositing protein matches the identified paraprotein clone.
KIMS Secunderabad — Dr. Aswini Dutt T (glomerular disease subspecialty), SPEP + UPEP + sFLC comprehensive screening, kidney biopsy with LM + IF + EM and light chain immunostaining (in-house), bone marrow biopsy coordination, joint nephrology-haematology MDT review for every MGRS case, bortezomib-based and daratumumab-based regimens, rituximab for B-cell clone MGRS, eculizumab for C3G-MGRS, transplant evaluation after clone suppression. NABH and NABL accredited. Call 040-4488-5000.